Expertise in
43
conditions

Dr. Siamak Daneshmand

Urology
USC Care Medical Group Inc
1520 San Pablo St, 
Los Angeles, CA 
Offers Telehealth
Expertise in
43
conditions
USC Care Medical Group Inc
1520 San Pablo St, 
Los Angeles, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Siamak Daneshmand is an Urologist in Los Angeles, California. Dr. Daneshmand is highly rated in 43 conditions, according to our data. His top areas of expertise are Bladder Cancer, Testicular Cancer, Muscle Invasive Bladder Cancer, Cystectomy, and Bladder Reconstruction.

His clinical research consists of co-authoring 397 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Urology
Licenses
Urology in CA
Hospital Affiliations
Keck Hospital Of USC
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

USC CARE MEDICAL GROUP INC
1520 San Pablo St, Los Angeles, CA 90033
Other Locations
USC CARE MEDICAL GROUP INC
1441 Eastlake Ave, Suite 2424, Los Angeles, CA 90089
USC CARE MEDICAL GROUP INC
1500 San Pablo St, Los Angeles, CA 90033

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Enrollment Status: Completed
Publish Date: May 22, 2025
Intervention Type: Drug
Study Drug: Atezolizumab
Study Phase: Phase 2
A Randomized Phase III Double Blind Clinical Trial Evaluating the Effect of Immune-Enhancing Nutrition on Radical Cystectomy Outcomes
A Randomized Phase III Double Blind Clinical Trial Evaluating the Effect of Immune-Enhancing Nutrition on Radical Cystectomy Outcomes
Enrollment Status: Active_not_recruiting
Publish Date: May 15, 2025
Intervention Type: Other, Dietary supplement
Study Phase: Phase 3
S1602, A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming With Intradermal BCG Before Intravesical Therapy for BCG-Naive High-Grade Non-muscle Invasive Bladder Cancer
S1602, A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming With Intradermal BCG Before Intravesical Therapy for BCG-Naive High-Grade Non-muscle Invasive Bladder Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 02, 2025
Intervention Type: Biological, Other
Study Drugs: Bacillus of Calmette-Guerin, Bacillus of Calmette-Guerin Tokyo-172 Strain Solution, Bacillus of Calmette-Guerin Tokyo-172 Strain Vaccine
Study Phase: Phase 3
A Prospective Observational Cohort Study to Assess MiRNA 371 for Outcome Prediction in Patients with Newly Diagnosed Germ Cell Tumors
A Prospective Observational Cohort Study to Assess MiRNA 371 for Outcome Prediction in Patients with Newly Diagnosed Germ Cell Tumors
Enrollment Status: Active_not_recruiting
Publish Date: February 26, 2025
Intervention Type: Procedure, Other
A Phase III Surgical Trial to Evaluate the Benefit of a Standard Versus an Extended Pelvic Lymphadenectomy Performed at Time of Radical Cystectomy for Muscle Invasive Urothelial Cancer
A Phase III Surgical Trial to Evaluate the Benefit of a Standard Versus an Extended Pelvic Lymphadenectomy Performed at Time of Radical Cystectomy for Muscle Invasive Urothelial Cancer
Enrollment Status: Completed
Publish Date: November 29, 2024
Intervention Type: Procedure
Study Phase: Not Applicable
A Randomized Phase II Study of Co-Expression Extrapolation (COXEN) With Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder Cancer
A Randomized Phase II Study of Co-Expression Extrapolation (COXEN) With Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder Cancer
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Drug
Study Drugs: Gemcitabine, Cisplatin, Methotrexate, Vinblastine, Doxorubicin, Filgrastim
Study Phase: Phase 2
Neoadjuvant Gemcitabine, Cisplatin, Plus Nivolumab in Patients With Muscle-invasive Bladder Cancer With Selective Bladder Sparing
Neoadjuvant Gemcitabine, Cisplatin, Plus Nivolumab in Patients With Muscle-invasive Bladder Cancer With Selective Bladder Sparing
Enrollment Status: Completed
Publish Date: June 27, 2024
Intervention Type: Drug
Study Drugs: Nivolumab, Gemcitabine, Cisplatin
Study Phase: Phase 2
Surgery in Early Metastatic Seminoma (SEMS): Phase II Trial of Retroperitoneal Lymph Node Dissection as First-Line Treatment for Testicular Seminoma With Isolated Retroperitoneal Disease (1-3cm)
Surgery in Early Metastatic Seminoma (SEMS): Phase II Trial of Retroperitoneal Lymph Node Dissection as First-Line Treatment for Testicular Seminoma With Isolated Retroperitoneal Disease (1-3cm)
Enrollment Status: Active_not_recruiting
Publish Date: March 18, 2024
Intervention Type: Procedure, Other
Study Phase: Not Applicable
Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations (PROOF 302)
Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations (PROOF 302)
Enrollment Status: Terminated
Publish Date: March 13, 2024
Intervention Type: Drug
Study Drug: Infigratinib
Study Phase: Phase 3
Efficacy of Continuous Infusion of Local Anesthesia After Radical Cystectomy: A Randomized, Double Blind, Placebo Controlled Study
Efficacy of Continuous Infusion of Local Anesthesia After Radical Cystectomy: A Randomized, Double Blind, Placebo Controlled Study
Enrollment Status: Withdrawn
Publish Date: April 16, 2019
Intervention Type: Other, Drug
Study Phase: Phase 3
View 9 Less Clinical Trials

396 Total Publications

Key Updates in Testicular Cancer: Optimizing Survivorship and Survival.
Key Updates in Testicular Cancer: Optimizing Survivorship and Survival.
Journal: American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting
Published: May 05, 2025
Similar Doctors
Expertise in
43
conditions
Dr. Hooman Djaladat
Urology
Expertise in
43
conditions
Dr. Hooman Djaladat
Urology

USC Care Medical Group Inc

1500 San Pablo St, 
Los Angeles, CA 
 (0.1 mi)
323-442-8444
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Hooman Djaladat is an Urologist in Los Angeles, California. Dr. Djaladat is highly rated in 43 conditions, according to our data. His top areas of expertise are Urothelial Cancer, Bladder Cancer, Upper Tract Urothelial Carcinoma (UTUC), Cystectomy, and Nephrectomy.

Expertise in
37
conditions
Dr. Mihir M. Desai
Urology
Expertise in
37
conditions
Dr. Mihir M. Desai
Urology

USC Care Medical Group Inc

1812 Verdugo Blvd, 
Glendale, CA 
 (9.8 mi)
818-790-7100
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Mihir Desai is an Urologist in Glendale, California. Dr. Desai is highly rated in 37 conditions, according to our data. His top areas of expertise are Bladder Cancer, Enlarged Prostate (BPH), Renal Cell Carcinoma (RCC), Aquablation, and Nephrectomy.

Expertise in
36
conditions
Dr. Monish Aron
Urology
Expertise in
36
conditions
Dr. Monish Aron
Urology

USC Care Medical Group Inc

1441 Eastlake Ave, Suite 2424, 
Los Angeles, CA 
 (0.2 mi)
323-442-2582
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Monish Aron is an Urologist in Los Angeles, California. Dr. Aron is highly rated in 36 conditions, according to our data. His top areas of expertise are Bladder Cancer, Renal Cell Carcinoma (RCC), Ureterocele, Nephrectomy, and Cystectomy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Daneshmand's expertise for a condition
ConditionClose
View All 11 Elite Conditions
View All 19 Distinguished Conditions
View All 13 Advanced Conditions
View All 38 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile